122 related articles for article (PubMed ID: 10918174)
1. Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma.
Birckbichler PJ; Bonner RB; Hurst RE; Bane BL; Pitha JV; Hemstreet GP
Cancer; 2000 Jul; 89(2):412-23. PubMed ID: 10918174
[TBL] [Abstract][Full Text] [Related]
2. Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Wehbi NK; Dugger AL; Bonner RB; Pitha JV; Hurst RE; Hemstreet GP
J Urol; 2002 May; 167(5):2215-21. PubMed ID: 11956481
[TBL] [Abstract][Full Text] [Related]
3. MAGI-2 in prostate cancer: an immunohistochemical study.
Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA
Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016
[TBL] [Abstract][Full Text] [Related]
4. Transrectal fine needle aspiration of prostate.
Jayaram G; Nakra N; Verma AK; Goel GD
J Assoc Physicians India; 1993 Jun; 41(6):364-6. PubMed ID: 7516326
[TBL] [Abstract][Full Text] [Related]
5. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.
Lee LM; Pan CC; Cheng CJ; Chi CW; Liu TY
Anticancer Res; 2001; 21(2B):1291-4. PubMed ID: 11396201
[TBL] [Abstract][Full Text] [Related]
8. Differential alternative splicing of human transglutaminase 4 in benign prostate hyperplasia and prostate cancer.
Cho SY; Choi K; Jeon JH; Kim CW; Shin DM; Lee JB; Lee SE; Kim CS; Park JS; Jeong EM; Jang GY; Song KY; Kim IG
Exp Mol Med; 2010 Apr; 42(4):310-8. PubMed ID: 20177144
[TBL] [Abstract][Full Text] [Related]
9. Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma.
Bisegna C; Gravina GL; Pierconti F; Martini M; Larocca L; Rossi P; Grimaldi P; Dolci S; Di Stasi S; Jannini EA
Andrology; 2020 Mar; 8(2):427-433. PubMed ID: 31433119
[TBL] [Abstract][Full Text] [Related]
10. Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue.
Andrews C; Humphrey PA
Am J Surg Pathol; 2014 Jul; 38(7):1007-12. PubMed ID: 24705308
[TBL] [Abstract][Full Text] [Related]
11. Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer.
An G; Meka CS; Bright SP; Veltri RW
Urology; 1999 Dec; 54(6):1105-11. PubMed ID: 10604718
[TBL] [Abstract][Full Text] [Related]
12. The utility of tissue transglutaminase as a marker of apoptosis during treatment and progression of prostate cancer.
Rittmaster RS; Thomas LN; Wright AS; Murray SK; Carlson K; Douglas RC; Yung J; Messieh M; Bell D; Lazier CB
J Urol; 1999 Dec; 162(6):2165-9. PubMed ID: 10569613
[TBL] [Abstract][Full Text] [Related]
13. Expression of the VEGF-receptor Flt-1 in benign, premalignant and malignant prostate tissues.
Hahn D; Simak R; Steiner GE; Handisurya A; Susani M; Marberger M
J Urol; 2000 Aug; 164(2):506-10. PubMed ID: 10893635
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
15. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
16. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
17. Expression of some selected cytokeratins and Ki67 protein in prostatic tumor: can these be used as tumor markers.
Adisa JO; Egbujo EC; Ibrahim B; Musa B; Madukwe J
Pan Afr Med J; 2015; 20():46. PubMed ID: 26090004
[TBL] [Abstract][Full Text] [Related]
18. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
19. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate.
Gelmini S; Tricarico C; Petrone L; Forti G; Amorosi A; Dedola GL; Serio M; Pazzagli M; Orlando C
Clin Chem Lab Med; 2003 Mar; 41(3):261-5. PubMed ID: 12705330
[TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
